Skip to main content
    F

    Fennec Pharmaceuticals Inc (FENC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.39
    -0.96 (-9.28%)

    Market Cap: $362.94M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(16/37)
    Avg Surprise
    -39.44%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.11
    Range$0.06 - $0.16
    5 analysts
    EPS RevisionsNo revisions (7d)
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.11-5.4%
    60d ago$0.11-5.4%
    30d ago$0.11-5.4%
    7d ago$0.11-7.0%
    Current$0.11
    Revenue Consensus
    $19M
    Range$18M - $20M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.21
    Range$0.09 - $0.41
    5 analysts
    Revenue Consensus
    $24M
    Range$22M - $25M
    6 analysts
    Last 12 of 38 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.21$0.09 - $0.41--5--
    Sep 26EST
    		-$0.11$0.06 - $0.16--5
    1
    2
    30d
    		-
    Jun 26
    Reported Aug 11
    		$0.05$0.01$0.00 - $0.05+400.00%Beat5
    0
    2
    30d
    		+145.5%
    Mar 26
    Reported May 14
    		$0.01N/A--70.24%Miss6
    0
    5
    30d
    		+125.0%
    Dec 25
    Reported Mar 24
    		$-0.10$0.04$-0.01 - $0.06-350.00%Miss5
    No revisions (30d)
    		-66.7%
    Sep 25
    Reported Nov 13
    		$-0.02$-0.02$-0.09 - $0.04+0.00%Beat2
    No revisions (30d)
    		+90.5%
    Jun 25
    Reported Aug 14
    		$-0.11$-0.03$-0.07 - $0.00-266.67%Miss4
    1
    0
    30d
    		+45.0%
    Mar 25
    Reported May 13
    		$-0.04$-0.08-+50.00%Beat4
    2
    1
    30d
    		-109.8%
    Dec 24
    Reported Mar 10
    		$-0.06N/A-+53.85%Beat4
    1
    0
    30d
    		+40.0%
    Sep 24
    Reported Nov 7
    		$-0.21$-0.08$-0.14 - $-0.02-162.50%Miss4
    No revisions (30d)
    		-200.0%
    Jun 24
    Reported Aug 13
    		$-0.20$0.02$-0.24 - $0.42-1100.00%Miss6
    No revisions (30d)
    		+4.8%
    Mar 24
    Reported May 14
    		$0.41$-0.04$-0.08 - $1.54+1125.00%Beat5
    No revisions (30d)
    		+278.3%
    Dec 23
    Reported Mar 21
    		$-0.10$-0.02$-0.10 - $0.03-400.00%Miss5
    1
    0
    30d
    		+61.5%
    Sep 23
    Reported Nov 6
    		$-0.07$-0.13$-0.15 - $-0.07+46.15%Beat6
    No revisions (30d)
    		+77.4%

    Key Metrics

    Valuation
    P/E Ratio-156.50EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-5.49%Operating Margin9.72%
    ROE-18.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage0.58x
    Current Ratio5.85xQuick Ratio5.66x
    Trading Statistics
    Beta1.21Avg Volume131.48K
    52-Week High$13.2552-Week Low$5.65

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.39
    SMA 20$10.36
    SMA 50$10.82
    SMA 200$9.26
    EMA 10$10.29
    EMA 20$10.39
    EMA 50$10.57
    EMA 200$9.68

    MACD

    Line: -0.13Signal: -0.10Hist: -0.03

    ADX

    ADX: 17.2+DI: 18.3-DI: 25.6

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down100.0
    PSAR$11.18

    Bollinger Bands

    Upper Band$11.09
    Lower Band$9.64
    %B Position1399%(Upper)
    Band Width-0.17

    RSI (14-Day)

    Neutral
    36.8

    Momentum Oscillators

    Stoch %K32.7
    Stoch %D41.9
    Williams %R-96.9
    ROC (10d)-9.0%
    Momentum-0.93
    CCI (20d)-183.4
    MFI (14d)45.9

    Volatility Measures

    ATR (14d)$0.62(6.6%)
    StdDev (20d)0.36
    Hist Vol57.1%(High)

    Volume Flow

    VWAP$9.78
    OBV8.1M
    AD Line-683.0K
    CMF (20d)-0.093

    Volume Metrics

    Avg Vol (20d)133.7K
    Vol Ratio1.2x
    VWMA (20d)$10.34

    Pivot Points

    R3$11.68
    R2$11.38
    R1$10.86
    Pivot Point$10.56
    S1$10.04
    S2$9.74
    S3$9.22

    Advanced Oscillators

    TSI-7.23
    Ultimate Osc41.3
    KST-32.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$17.87M$15.11M$13.78M$12.46M$9.65M$8.75M$7.92M$6.97M$7.26M$25.38M$9.73M$6.51M
    Cost of Revenue$721,000$570,000$1.76M$660,000$967,000$373,000$669,000$1.36M$608,000$550,000$685,000$331,000
    Gross Profit$17.15M$14.54M$12.01M$11.80M$8.69M$8.38M$7.26M$5.62M$6.65M$24.83M$9.05M$6.18M
    Operating Expenses$15.42M$14.66M$14.57M$11.99M$11.42M$9.19M$8.19M$10.82M$11.69M$11.08M$10.87M$7.20M
    R&D$118,000$49,000$20,000$29,000$107,000$94,000$50,000$97,000$157,000$3,000$32,000$12,000
    SG&A$4.64M$3.19M$8.44M$6.75M$6.53M$5.87M$4.20M$6.12M$6.86M$5.87M$6.97M$3.81M
    Operating Income$1.74M$-119,000$-2,553,000$-189,000$-2,732,000$-808,000$-934,000$-5,202,000$-5,039,000$13.74M$-1,818,000$-1,017,000
    Interest Income$287,000$339,000$228,000$152,000$171,000$236,000$399,000$516,000$570,000$197,000$0$102,000
    Interest Expense$3,000$7,000$2.36M$598,000$607,000$605,000$991,000$1.05M$1.07M$1.05M$1.21M$928,000
    Income Before Tax$2.02M$0$-4,680,000$-638,000$-3,152,000$0$-1,620,000$-5,735,000$-5,553,000$12.84M$-2,682,000$-1,867,000
    Income Tax Expense$42,000$0$0$0$0$0$0$0$0$0$0$0
    Net Income$1.97M$201,000$-4,786,000$-638,000$-3,152,000$-1,165,000$-1,985,000$-5,735,000$-5,553,000$12.84M$-2,682,000$-1,867,000
    EBITDA$1.76M$-105,000$-2,422,000$-180,000$-2,678,000$-757,000$-907,000$-5,159,000$-5,007,000$14.44M$-1,742,000$-969,000
    EBIT$1.73M$-131,000$-2,552,000$-192,000$-2,716,000$-796,000$-1,028,000$-5,205,000$-5,056,000$13.69M$-1,812,000$-1,041,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FENC

    News

    Fennec Pharmaceuticals sets Q3FY26 earnings release for November 12

    Fennec Pharmaceuticals Inc. announced it will release its third-quarter 2026 financial results before the opening of U.S. markets on Thursday, November 12...

    scanx.trade•11/6/26•Neutral

    An 8:30 a.m. call will cover Fennec's quarterly results on Nov. 12.

    Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) announced it will release its third quarter 2026 financial results before U.S. markets open on November 12...

    Stock Titan•11/6/26•Neutral

    Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026

    Fennec Pharmaceuticals Inc. announced it will release its third-quarter 2026 financial results before the U.S. financial markets open on Thursday, November 12...

    The Manila Times•11/6/26•Neutral

    Form 4 FENNEC PHARMACEUTICALS INC.: Terry L. Evans (Chief Commercial Officer) For: 31 October

    This article reports on a Form 4 filing for Fennec Pharmaceuticals Inc., detailing a transaction involving Terry L. Evans, the Chief Commercial Officer...

    Investing.com South Africa•11/3/26•Neutral

    Award shares bring Fennec Pharmaceuticals (FENC) CEO’s direct holding to 70,844 shares.

    Jeffrey S. Hackman, CEO of Fennec Pharmaceuticals Inc. (FENC), acquired 1,159 common shares on October 31, 2026. These shares were released from restrictions related to an award made on March 28...

    Stock Titan•11/3/26•Neutral

    FENC Valuation and Fair Value

    P/E
    -156.5x
    Forward P/E
    12.2x
    PEG
    1.5x
    P/B
    7.6x
    See GNG's fair value

    FENC Profitability: Margins, ROIC and FCF

    Gross margin
    93.7%
    Operating margin
    9.7%
    Net margin
    -5.5%
    ROE
    -18.6%

    FENC Competitors

    CompanyTicker
    Wellgistics Health, Inc. Common StockWGRX
    Orthofix Medical IncOFIX
    Embecta CorpEMBC
    Zura Bio Limited Class A Ordinary SharesZURA
    Simulations Plus IncSLP
    Rezolute IncRZLT
    Avalo Therapeutics IncAVTX
    Contineum Therapeutics, Inc. Class A Common StockCTNM

    Sector: Healthcare

    FENC Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    2
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    FENC Bull Case vs Bear Case

    Bull case

    • FENC grew quarterly revenue 85.2% year over year.
    • 100.0% of FENC's analyst ratings are Buy or Strong Buy.

    Bear case

    • FENC has a -5.5% net profit margin.
    • FENC beat EPS estimates in 37.5% of its last 8 reported quarters.

    FENC Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -43.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.11
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    FENC Earnings Date

    FENC reports Mar 22, 2027, after the close. The date is estimated.

    FENC Earnings Call

    The latest FENC earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    FENC ETF Holders

    GNG tracks 3 ETFs that hold FENC. The largest weights:

    1. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    2. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    3. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    Open the ETF Stock Exposure tool for FENC

    See insider activity

    Frequently Asked Questions About FENC

    When does FENC report earnings?

    Fennec Pharmaceuticals Inc (FENC) is expected to report earnings on Mar 22, 2027.

    Does FENC pay dividends?

    Fennec Pharmaceuticals Inc (FENC) does not currently pay a regular dividend.

    What is FENC's market cap?

    Fennec Pharmaceuticals Inc (FENC) has a market capitalization of $362.94M with a current stock price of $9.39.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In